阿斯利康首席执行官帕斯卡尔·索里奥特表示，该公司必须以"中国速度"运营，以防止被更具创新性的竞争对手超越，避免重蹈西方汽车行业衰退的覆辙1。索里奥特指出，中国制药公司在抗体偶联药物和细胞疗法等新技术领域投入巨大，对欧美制药业构成潜在威胁1。
阿斯利康对未来增长前景保持乐观态度1。该公司制定了2030年实现年销售额80亿美元的增长目标，相比去年的59亿美元有显著提升1。在2026年上半年，阿斯利康收入达到307亿英镑，按不变汇率计算同比增长6%1。该公司心脏病药物瓦依努亚本月在临床试验中意外失败1。索里奥特表示正与英国新领导人安迪·伯纳姆政府就美英药品协议进行讨论1。
Pascal Soriot, chief executive of AstraZeneca, has warned that Western pharmaceutical companies must operate at a significantly faster pace to avoid falling behind more innovative competitors, particularly from China.1 Soriot stated that the company must "move much faster," emphasizing that the organization operates according to "Chinese speed."1 He highlighted that Chinese pharmaceutical firms are making substantial investments in emerging technologies including antibody-drug conjugates and cell therapies, posing a potential threat to European and American pharmaceutical manufacturers.1
AstraZeneca remains confident in its growth target of achieving $8 billion in annual sales by 2030, up from $5.9 billion in the previous year.1 In the first half of 2026, the company reported revenues of £30.7 billion, representing 6% growth on a constant currency basis.1 However, the company faced a setback this month when its heart disease drug Wainua unexpectedly failed in clinical trials.1 Soriot indicated that AstraZeneca is engaged in discussions with the new UK government regarding a US-UK pharmaceutical agreement.1
评论
还没有评论，欢迎留下第一条。